Literature DB >> 24649072

Expression of CD39 mRNA is altered in the peripheral blood of patients with allergic asthma.

Lin-Lin Wang1, Ping-Hua Tang2, Chao-Guo Shi1, Ying-Huan Wan1, Wei Tang1, Xia-Xiao Hou1, Na-Li Pan1, Yu-Bao Shi1, Qin-Lian Tao1.   

Abstract

The ectoenzyme CD39 hydrolyzes extracellular adenosine 5'-triphosphate (ATP), which possesses pro-inflammatory properties. However, the role of CD39 in allergic asthma has not been fully elucidated. A total of 18 patients with persistent asthma who were allergic to house dust mites and 19 healthy volunteers were enrolled in this study. The expression of CD39, GATA3, RAR-related orphan receptor γ (ROR-γt) and forkhead box P3 (FoxP3) mRNA in peripheral blood mononuclear cells (PBMCs) was determined by SYBR-Green I quantitative polymerase chain reaction (qPCR). The cytokines interleukin (IL)-4, IL-17A, transforming growth factor β (TGF-β) and DP.sIgE were detected by enzyme-linked immunosorbent assay. Our data demonstrated that the expression of CD39 mRNA in PBMCs from asthmatic patients was significantly lower compared to that in normal controls [(1.49±0.59)×10-3 vs. (2.17±0.77)×10-3, respectively; P<0.01]. CD39 mRNA was negatively correlated with serum IL-4, IL-17A and GATA3 expression (r=-0.468, P<0.05; r=-0.550, P<0.05; and r=-0.424, P<0.01, respectively) and positively correlated with FoxP3 and TGF-β expression (r=0.373, P<0.05; and r=0.425, P<0.05, respectively). There was no obvious correlation between CD39 and ROR-γt expression (r=-0.259, P=0.122). These data suggested that CD39 mRNA expression was downregulated in allergic asthma, which was positively correlated with serum IL-4, IL-17A and GATA3 expression and negatively correlated with serum TGF-β and FoxP3 expression, whereas there was no correlation with ROR-γt. Therefore, it was hypothesized that CD39 may participate in the occurrence and progression of allergic asthma.

Entities:  

Keywords:  CD39; allergic asthma; inflammatory factors

Year:  2013        PMID: 24649072      PMCID: PMC3917046          DOI: 10.3892/br.2013.196

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  29 in total

1.  Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.

Authors:  A Ohta; M Sitkovsky
Journal:  Nature       Date:  2001 Dec 20-27       Impact factor: 49.962

Review 2.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

3.  CD39 modulates IL-1 release from activated endothelial cells.

Authors:  M Imai; C Goepfert; E Kaczmarek; S C Robson
Journal:  Biochem Biophys Res Commun       Date:  2000-04-02       Impact factor: 3.575

4.  The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells.

Authors:  Ivaylo I Ivanov; Brent S McKenzie; Liang Zhou; Carlos E Tadokoro; Alice Lepelley; Juan J Lafaille; Daniel J Cua; Dan R Littman
Journal:  Cell       Date:  2006-09-22       Impact factor: 41.582

5.  Adenosine inhibits the release of interleukin-1beta in activated human peripheral mononuclear cells.

Authors:  Sandor Sipka; Ildikó Kovács; Sándor Szántó; Gyula Szegedi; László Brugós; Geza Bruckner; A József Szentmiklósi
Journal:  Cytokine       Date:  2005-08-21       Impact factor: 3.861

6.  P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide.

Authors:  M Warny; S Aboudola; S C Robson; J Sévigny; D Communi; S P Soltoff; C P Kelly
Journal:  J Biol Chem       Date:  2001-05-10       Impact factor: 5.157

7.  Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion.

Authors:  S Huang; S Apasov; M Koshiba; M Sitkovsky
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

8.  Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation.

Authors:  Maria A Curotto de Lafaille; Nino Kutchukhidze; Shiqian Shen; Yi Ding; Herman Yee; Juan J Lafaille
Journal:  Immunity       Date:  2008-07-18       Impact factor: 31.745

Review 9.  GATA-3 promotes Th2 responses through three different mechanisms: induction of Th2 cytokine production, selective growth of Th2 cells and inhibition of Th1 cell-specific factors.

Authors:  Jinfang Zhu; Hidehiro Yamane; Javier Cote-Sierra; Liying Guo; William E Paul
Journal:  Cell Res       Date:  2006-01       Impact factor: 25.617

10.  The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway.

Authors:  Akio Ohta; Radhika Kini; Akiko Ohta; Meenakshi Subramanian; Manasa Madasu; Michail Sitkovsky
Journal:  Front Immunol       Date:  2012-07-05       Impact factor: 7.561

View more
  4 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Long-lived regulatory T cells generated during severe bronchiolitis in infancy influence later progression to asthma.

Authors:  Jason P Lynch; Rhiannon B Werder; Bodie F Curren; Md Al Amin Sikder; Ashik Ullah; Ismail Sebina; Ridwan B Rashid; Vivian Zhang; John W Upham; Geoff R Hill; Raymond J Steptoe; Simon Phipps
Journal:  Mucosal Immunol       Date:  2020-02-17       Impact factor: 7.313

3.  The Cell Research Trends of Asthma: A Stem Frequency Analysis of the Literature.

Authors:  Wenchao Tang; Yi Shang; Bin Xiao; Peitong Wen; Ruoyun Lyu; Ke Ning
Journal:  J Healthc Eng       Date:  2018-08-23       Impact factor: 2.682

4.  IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression.

Authors:  Fengqin Fang; Wenqiang Cao; Yunmei Mu; Hirohisa Okuyama; Lingjie Li; Jingtao Qiu; Cornelia M Weyand; Jörg J Goronzy
Journal:  JCI Insight       Date:  2022-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.